HRTS Tema Obesity & Cardiometabolic ETF Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:08
Mar 09
Mar 09
GLP-1 adoption to rise broadly.
Nearly one in seven Americans take a GLP-1 and 20% have tried them. Adoption will rise, possibly over half of Americans, especially those with family obesity, often at lower doses via compounding/gray market. In theory, obesity could be eradicated.
HIGH
11:01
Jan 02
Jan 02
Bio subthemes rotate within Korean market.
Within Korean biotech, Kim expects several themes to rotate: ADC, bispecific antibodies, obesity, MASH, dementia, and hair loss where policy issues have emerged. He views these as smaller thematic trades rather than one single sector call.
MED
22:10
Jan 01
Jan 01
Obesity and heart drugs expand
Within healthcare, Goldman highlighted expansion into next-generation obesity treatments and heart disease therapies as AI/productivity beneficiary areas.
MED
About HRTS Investor Commentary
Across the available history and selected sources, Buzzberg tracks HRTS (Tema Obesity & Cardiometabolic ETF) across 3 sources: 2 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 67% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: Andrew Huberman, Kim Dong-yeop, Park Myung-seok.